Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | CYBB | P04839 | 1/20 | 0.35 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.35 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.35 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.34 |
| ▸ | STS | P08842 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26890664 | 0.85 | MEN1 (0.42) | MEN1KMT2AGRM5ESR2CYBB | |
| SCHEMBL25434759 | 0.84 | STS (0.38) | MEN1KMT2AGRM5ESR2GPR119 | |
| SCHEMBL25434099 | 0.81 | MEN1 (0.40) | MEN1KMT2AGRM5ESR2CYBB | |
| SCHEMBL26686738 | 0.79 | MEN1 (0.43) | MEN1KMT2AESR2CYBBNOX5 | |
| SCHEMBL25335687 | 0.79 | MEN1 (0.43) | MEN1KMT2AESR2CYBBNOX5 | |
| SCHEMBL25337280 | 0.77 | NR1H2 (0.42) | MEN1KMT2AESR2CYBBNOX5 | |
| SCHEMBL26687047 | 0.77 | ADORA1 (0.42) | MEN1KMT2AESR2CYBBNOX5 | |
| SCHEMBL24535149 | 0.76 | MEN1 (0.40) | MEN1KMT2AESR2CYBBNOX5 | |
| SCHEMBL30793901 | 0.76 | MEN1 (0.38) | MEN1KMT2AESR2CYBBNOX5 | |
| SCHEMBL30793245 | 0.76 | ESR2 (0.38) | MEN1KMT2AGRM5ESR2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | MEN1 551/4885KMT2A 2868/4885GRM5 1619/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | MEN1 551/4885KMT2A 2868/4885GRM5 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.